-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Biopharmaceutical company Immunicum today announced that in the updated data of the phase II MERECA randomized trial, ilixadencel combined with sunitinib has achieved positive results in the first-line treatment of patients with metastatic renal cell carcinoma (mRCC).
Sunitinib
As of February 2021, the separation of the Kaplan-Meier survival curve is conducive to the combination of ilixadencel.
The proportion of surviving patients in the ilixadencel combination treatment group was 41% (23 out of 56 survived), compared to 30% in the control group (9 out of 30 survived).
Original source:
Original source:https://target="_blank" rel="noopener">https:// style="vertical-align: inherit;"> https:// leave a message here